Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

Igor Kiss; Zbynek Bortlicek; Bohuslav Melichar; Alexandr Poprach; Jana Halamkova; Rostislav Vyzula; Ladislav Dusek; Tomas Buchler

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

【24h】

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

机译：贝伐单抗联合化疗在转移性结直肠癌不同治疗方案中的疗效和毒性。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The data describe efficacy of bevacizumab with chemotherapy for different treatment lines in a large patient cohort.

机译：数据描述了贝伐单抗联合化疗对大患者队列中不同治疗方案的疗效。

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2014年第2期|共6页
作者
Igor Kiss; Zbynek Bortlicek; Bohuslav Melichar; Alexandr Poprach; Jana Halamkova; Rostislav Vyzula; Ladislav Dusek; Tomas Buchler;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. [J] . Igor Kiss, Zbynek Bortlicek, Bohuslav Melichar, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第2期

机译：贝伐单抗联合化疗在转移性结直肠癌不同治疗方案中的疗效和毒性。
2. Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma [J] . IGOR KISS, ZBYNEK BORTLICEK, BOHUSLAV MELICHAR, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第Pta2期

机译：贝伐单抗与不同治疗转移结直肠癌的化疗组合的疗效和毒性
3. Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma [J] . IGOR KISS, ZBYNEK BORTLICEK, BOHUSLAV MELICHAR, Anticancer Research: International Journal of Cancer Research and Treatment . 2014,第Pta2期

机译：贝伐单抗联合化疗在转移性结直肠癌不同治疗方案中的疗效和毒性
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma [D] . ADiLiJiang ALiMu 2019

机译：下一代基于测序的转录组预测贝伐单抗联合替莫唑胺在成胶质细胞瘤中的疗效。
6. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy) bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. [O] . M Hoyle, L Crathorne, J Peters, -1

机译：一线化疗后西妥昔单抗（单药或联合化疗）贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估书和第118号技术评估书的一部分复审：系统的复审和经济模型。
7. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model [O] . Hoyle, M, Crathorne, Louise, Peters, J, 2013

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

摘要

著录项

相似文献

相关主题

期刊订阅